LogicBio Therapeutics, Inc. (LOGC): History, Ownership, Mission, How It Works & Makes Money

Are you intrigued by companies revolutionizing genetic medicine?

LogicBio Therapeutics, Inc. (LOGC) aimed to transform the landscape with its GeneRide technology, offering hope for rare genetic disorders. While acquired by Alexion, AstraZeneca Rare Disease in October 2022, its legacy of pioneering gene delivery and editing platforms continues to shape genomic medicine. Delve into the history, mission, and innovative approaches that once defined LogicBio, including its $43 million in revenues for the fiscal year 2024.

LogicBio Therapeutics, Inc. (LOGC) History

The story of LogicBio Therapeutics is one of scientific innovation and strategic shifts in the competitive landscape of genetic medicine. From its inception to its acquisition, the company navigated the complexities of developing gene therapies, particularly for rare diseases.

LogicBio Therapeutics Founding Timeline

Year established

LogicBio Therapeutics was established in 2015.

Original location

The company was originally located in Cambridge, Massachusetts.

Founding team members

The founding team included individuals with expertise in gene therapy and biotechnology, driving the initial scientific direction of the company.

Initial capital/funding

LogicBio secured an initial seed funding of $45 million in 2015, led by investors such as Arix Bioscience and Pontifax.

LogicBio Therapeutics Evolution Milestones

LogicBio Therapeutics Transformative Moments

Several key decisions and events significantly shaped LogicBio's trajectory:

• Focus on GeneRide™ Platform: The company's core technology, GeneRide™, aimed to insert therapeutic genes into the genome without the use of viral vectors, offering a novel approach to gene therapy.
• Clinical Trial Challenges: The discontinuation of LB-001, a leading program targeting MMA, due to clinical results, prompted a strategic reassessment and pipeline restructuring.
• Acquisition by Ultragenyx: The acquisition by Ultragenyx in 2023 marked a pivotal moment, integrating LogicBio’s assets and expertise into a larger pharmaceutical company focused on rare disease treatments.

These moments reflect LogicBio's journey through innovation, clinical development hurdles, and strategic realignments, ultimately leading to its integration into Ultragenyx to further advance genetic medicine.

LogicBio Therapeutics, Inc. (LOGC) Ownership Structure

Understanding LogicBio Therapeutics, Inc.’s ownership structure provides insights into who controls the company and how it's governed. As a publicly traded entity before its acquisition, ownership was distributed among various shareholders.

LogicBio Therapeutics, Inc.'s Current Status

LogicBio Therapeutics was a public company before being acquired by REGENXBIO Inc. in 2022. The company is no longer trading on the stock market.

LogicBio Therapeutics, Inc.'s Ownership Breakdown

As a company acquired in 2022, the latest ownership data available refers to the period before the acquisition. Major shareholders likely included institutional investors, individual shareholders, and potentially some corporate entities. However, specific percentages would have fluctuated based on trading activity.

LogicBio Therapeutics, Inc.'s Leadership

Before its acquisition, LogicBio Therapeutics was guided by a leadership team that included:

• Nolan Townsend: Former Chief Executive Officer
• Daniel Gruskin, M.D.: Former Chief Medical Officer

These individuals played key roles in steering the company's strategy and operations prior to the acquisition by REGENXBIO.

For more insights into investor profiles, check out: Exploring LogicBio Therapeutics, Inc. (LOGC) Investor Profile: Who’s Buying and Why?

LogicBio Therapeutics, Inc. (LOGC) Mission and Values

LogicBio Therapeutics, Inc. aimed to develop medicines to treat genetic diseases by editing genes in vivo. While the company is no longer active, its mission and values reflected a commitment to innovation and patient well-being.

LogicBio Therapeutics' Core Purpose

Official mission statement

LogicBio's mission statement was to develop medicines to durably treat genetic diseases. This involved:

• Developing in vivo gene editing and delivery platforms.
• Focusing on diseases where there was a significant unmet medical need.
• Creating potentially curative treatments for patients.

Vision statement

While a specific vision statement isn't readily available, the company's actions and communications suggested a vision focused on:

• Becoming a leader in the field of in vivo gene editing.
• Transforming the lives of patients with genetic diseases through innovative therapies.
• Building a sustainable company that could continue to develop and deliver these therapies.

Company slogan/tagline

Information on a specific company slogan or tagline is not available in the provided search results. For more in-depth information, check this link: Mission Statement, Vision, & Core Values of LogicBio Therapeutics, Inc. (LOGC).

LogicBio Therapeutics, Inc. (LOGC) How It Works

LogicBio Therapeutics, Inc. (LOGC) was a genome editing company focused on developing medicines to treat rare diseases, particularly in pediatric patients, using its proprietary GeneRide™ platform and AAV sLIT technology.

LogicBio's Product/Service Portfolio

LogicBio's Operational Framework

LogicBio Therapeutics operated with a focus on developing treatments for rare genetic disorders through advanced genome editing technologies. Here’s how they operated:

• Research and Development: Focused on advancing its GeneRide™ platform and AAV sLIT technology to develop treatments for genetic disorders.
• Clinical Trials: Conducted clinical trials to evaluate the safety and efficacy of its product candidates, such as LB-001 for MMA and LB-101 for Crigler-Najjar Syndrome Type 1.
• Partnerships and Collaborations: Collaborated with academic institutions and other companies to enhance its research and development efforts.
• Manufacturing: Worked on scalable manufacturing processes to support clinical trials and potential commercialization.

LogicBio's Strategic Advantages

LogicBio’s strategic advantages revolved around its innovative technology platforms and targeted approach to treating rare genetic diseases:

• GeneRide™ Platform:
  • Enabled in situ correction of disease-causing genes without the need for exogenous gene insertion.
  • Designed to provide long-lasting therapeutic effects from a single treatment.
• AAV sLIT Technology:
  • Utilized a modified adeno-associated virus (AAV) vector to deliver therapeutic genes to the liver.
  • Aimed to provide stable and efficient gene expression in target cells.
• Focus on Rare Genetic Diseases:
  • Addressed unmet medical needs in patient populations with limited treatment options.
  • Potential for orphan drug designation and accelerated regulatory pathways.

To gain more insights into the financial aspects, you can explore this resource: Breaking Down LogicBio Therapeutics, Inc. (LOGC) Financial Health: Key Insights for Investors

LogicBio Therapeutics, Inc. (LOGC) How It Makes Money

LogicBio Therapeutics, Inc. (LOGC) focused on developing medicines to treat rare genetic diseases, primarily through gene therapy. However, it is important to note that LogicBio has ceased operations and as of November 2022, the company's assets were acquired by a private company. Therefore, the following information is based on its historical business model and financial status before the acquisition.

LogicBio Therapeutics, Inc. Revenue Breakdown

Since LogicBio Therapeutics was a development-stage biotechnology company, it did not generate revenue from product sales. Its revenue primarily consisted of collaboration agreements and licensing deals.

LogicBio Therapeutics, Inc. Business Economics

LogicBio's business economics were centered around the high-risk, high-reward model typical of biotechnology companies. Key aspects included:

• R&D Investments: A significant portion of their expenditure was dedicated to research and development of GeneRide™ platform and other genetic medicine technologies.
• Partnerships: Strategic alliances and collaborations were crucial for funding and expertise. These partnerships provided upfront payments, milestone payments, and potential royalties on future product sales.
• Intellectual Property: Patents and proprietary technology formed a critical asset base, attracting investment and partnership opportunities.
• Clinical Trials: The success of clinical trials was paramount. Positive results could lead to lucrative licensing deals or eventual commercialization.

More insights about company's mission can be found here: Mission Statement, Vision, & Core Values of LogicBio Therapeutics, Inc. (LOGC).

LogicBio Therapeutics, Inc. Financial Performance

Given that LogicBio was acquired in November 2022 and is no longer operating, its recent financial performance reflects its state prior to acquisition. Here are some key points:

• Cash Position: Monitoring cash reserves was vital to fund ongoing research and development. LogicBio's financial reports would have detailed its cash burn rate and runway.
• Operating Expenses: These included R&D expenses, general and administrative costs. Managing these effectively was critical to extending the company's operational lifespan.
• Net Losses: As a development-stage company, LogicBio consistently reported net losses, which were offset by financing activities such as equity offerings and debt financing.
• Liquidity: Assessing its liquidity position was crucial to understanding its ability to meet short-term obligations and fund its operations until it could achieve sustainable revenue generation or secure additional funding.

The acquisition in November 2022 marked a significant turning point, reflecting the challenges and risks inherent in the biotechnology industry, particularly for companies reliant on long-term research and development without established revenue streams.

LogicBio Therapeutics, Inc. (LOGC) Market Position & Future Outlook

The company, previously focused on developing genetic medicine for early-childhood diseases, has undergone significant changes, including a merger and a shift in strategic direction which impacts its market position and future outlook. Given these substantial changes, assessing the competitive landscape, opportunities, and challenges requires considering the new entity formed through the merger.

Competitive Landscape

Due to the acquisition of the company, a direct market share comparison with previous competitors is not applicable. The competitive landscape now depends on the acquirer's focus and market.

Opportunities & Challenges

The opportunities and challenges for the company are now those of the acquiring entity, and depend on its strategic goals following the acquisition.

Industry Position

The company's industry position has fundamentally changed. It is no longer an independent entity but part of a larger organization. Its future impact on the genetic medicine field depends on how the acquirer leverages its assets and technologies. Here are key considerations:

• Integration Strategy: The success hinges on how well the company's assets are integrated into the acquirer's existing structure and strategy.
• Pipeline Potential: The continued development and potential commercialization of the company's previous pipeline programs will be a key factor.
• Market Dynamics: The evolving landscape of genetic medicine, including regulatory changes and competitive pressures, will influence its trajectory.

To gain more insights into the investors and their perspectives, check out: Exploring LogicBio Therapeutics, Inc. (LOGC) Investor Profile: Who’s Buying and Why?